[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2019

August 2019 | 60 pages | ID: C7F29E6AC38EN
DelveInsight

US$ 1,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 Hours

"Chronic Neuropathic Pain (CNP) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Neuropathic Pain pipeline landscape is provided which includes the disease overview and Chronic Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Chronic Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chronic Neuropathic Pain Understanding

According to the International Association for the Study of Pain (IASP), chronic neuropathic pain is chronic pain caused by a lesion or disease of the somatosensory nervous system. The pain may be spontaneous or evoked, as an increased response to a painful stimulus (hyper-algesia) or a painful response to a normally non-painful stimulus (allodynia). The diagnosis of chronic neuropathic pain requires a history of nervous system injury or disease and a neuro-anatomically plausible distribution of the pain. Negative (e.g., decreased or loss of sensation) and positive sensory symptoms or signs (e.g., allodynia or hyperalgesia) indicating the involvement of the somatosensory nervous system must be compatible with the innervation territory of the affected nervous structure. CNP is a major factor contributing to the global burden of disease. Its prevalence ranges between 6.9% and 10% of the general population. Chronic pain is defined as pain that lasts or recurs for more than three months. With CNP, the nerve fibers themselves might be damaged, dysfunctional, or injured. These damaged nerve fibers send incorrect signals to other pain centers. The impact of a nerve fiber injury includes a change in nerve function both at the site of injury and areas around the injury. Chronic manifestations commence with subtle pain and develop gradually.

Chronic Neuropathic Pain Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Chronic Neuropathic Pain targeted therapeutics development with respective active and dormant or discontinued projects. Chronic Neuropathic Pain pipeline report covers 18+ companies. Some of the key players include, Algiax Pharmaceuticals (AP-325), Syntrix Biosystems (Desmetramadol), Centrexion Therapeutics (CNTX 2022) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Chronic Neuropathic Pain Analytical Perspective by DelveInsight
  • In-depth Chronic Neuropathic Pain Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Chronic Neuropathic Pain Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Chronic Neuropathic Pain report provides an overview of therapeutic pipeline activity for Chronic Neuropathic Pain across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Chronic Neuropathic Pain therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Chronic Neuropathic Pain Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Chronic Neuropathic Pain
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Chronic Neuropathic Pain to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Chronic Neuropathic Pain R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Chronic Neuropathic Pain in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chronic Neuropathic Pain to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. CHRONIC NEUROPATHIC PAIN

2.1. Chronic Neuropathic Pain Disease Overview
2.2. Chronic Neuropathic Pain History
2.3. Chronic Neuropathic Pain Symptoms
2.4. Chronic Neuropathic Pain Causes
2.5. Chronic Neuropathic Pain Pathophysiology
2.6. Chronic Neuropathic Pain Diagnosis
  2.6.1. Diagnostic Guidelines

3. CHRONIC NEUROPATHIC PAIN CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. CHRONIC NEUROPATHIC PAIN - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Chronic Neuropathic Pain companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Chronic Neuropathic Pain Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Chronic Neuropathic Pain Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. CHRONIC NEUROPATHIC PAIN PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. CHRONIC NEUROPATHIC PAIN -PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. AP-325- Algiax Pharmaceuticals
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
  6.1.2. Desmetramadol- Syntrix Biosystems
    6.1.2.1. Product Description
      6.1.2.1.1. Product Overview
      6.1.2.1.2. Mechanism of Action
    6.1.2.2. Research and Development
      6.1.2.2.1. Clinical Studies
        6.1.2.2.1.1. Detailed Study Description
        6.1.2.2.1.2. Study Results
        6.1.2.2.1.3. Clinical Trials: Tabular View
    6.1.2.3. Product Development Activities
      6.1.2.3.1. Tabulated Product Summary
        6.1.2.3.1.1. General Description Table
  6.1.3. CNTX 2022- Centrexion Therapeutics
    6.1.3.1. Product Description
      6.1.3.1.1. Product Overview
      6.1.3.1.2. Mechanism of Action
    6.1.3.2. Research and Development
      6.1.3.2.1. Clinical Studies
        6.1.3.2.1.1. Detailed Study Description
        6.1.3.2.1.2. Study Results
        6.1.3.2.1.3. Clinical Trials: Tabular View
    6.1.3.3. Product Development Activities
      6.1.3.3.1. Tabulated Product Summary
        6.1.3.3.1.1. General Description Table
To be continued in the report…………………………

7. RECENT TECHNOLOGIES

8. CHRONIC NEUROPATHIC PAIN KEY COMPANIES

8.1. GlaxoSmithKline
8.2. Chiesi Farmaceutici
8.3. Novartis
8.4. Esteve
8.5. Neuromed Pharmaceuticals
8.6. Glenmark Pharmaceuticals
8.7. Diamyd Medical
8.8. Amgen
8.9. AstraZeneca
8.10. Tools4Patient
8.11. AstraZeneca
8.12. Newron Pharmaceuticals
8.13. Avigen
8.14. Grunenthal
8.15. Immune Pharmaceuticals
8.16. Algiax Pharmaceuticals

9. CHRONIC NEUROPATHIC PAIN KEY PRODUCTS

9.1. 4030W92
9.2. Indantadol
9.3. Olodanrigan
9.4. E 52862
9.5. Z 160
9.6. GRC 17536
9.7. NP 2
9.8. Fulranumab
9.9. AZD 6088
9.10. T4P 1001
9.11. AZD 2066
9.12. Ralfinamide
9.13. Research programme: neuropathic pain and drug abuse therapies
9.14. Axomadol
9.15. Amitriptyline/ketamine
9.16. AP-325
9.17. Desmetramadol

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. CHRONIC NEUROPATHIC PAIN - UNMET NEEDS

12. CHRONIC NEUROPATHIC PAIN - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Chronic Neuropathic Pain Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Chronic Neuropathic Pain Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Chronic Neuropathic Pain companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Chronic Neuropathic Pain Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

GlaxoSmithKline
Chiesi Farmaceutici
Novartis
Esteve
Neuromed Pharmaceuticals
Glenmark Pharmaceuticals
Diamyd Medical
Amgen
AstraZeneca
Tools4Patient
AstraZeneca
Newron Pharmaceuticals
Avigen
Grunenthal
Immune Pharmaceuticals


More Publications